Oncology Stock Gains 12% in Three Months: What's Driving It?

Oncology Stock Gains 12% in Three Months: What’s Driving It? CG Oncology’s (CGON) shares rose 12% over the past three months, outpacing the industry’s 1.1% decline. The move is tied to investor optimism around cretostimogene grenadenorepvec, the company’s lead bladder cancer therapy, alongside accelerating regulatory momentum and a reported strong balance sheet. CG Oncology is preparing its first biologics license application (BLA) for high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS), with or without Ta/T1 disease. Management expects to complete the BLA submission in Q4 2026 after alignment discussions with the FDA. In mid-May, the company reported positive Phase II CORE-008 data in CORE-008 Cohort CX with gemcitabine, including 96.0% high-grade event-free survival at three months and no grade 3+ treatment-related adverse events or treatment-related deaths.